ArticleBMJ open2023
Prevalence, awareness, treatment and control of dyslipidaemia and their determinants: results from a population-based survey of 60 283 residents in eastern China.
Article in BMJ open, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Prevalence and determinants of dyslipidemia among residents of Kurdistan Region of Iraq; a community-based study.BMC research notes · 2026Article
- Prevalence and risk factor analysis of early-onset dyslipidemia-a cross-sectional study of 3.7 million population.Lipids in health and disease · 2026Article
- Article
- Time Perspective and Health Behaviors in Chronic Disease Patients: A Chain Mediation Model of Illness Perception via Temporal Self-Regulation Theory.Behavioral sciences (Basel, Switzerland) · 2025Article
- Low awareness of lipid disorders amongst individuals despite their high prevalence.Irish journal of medical science · 2025Article
- Cardiovascular disease risk factors are associated with conventional lipids and apolipoproteins in South African adults of African ancestry.Lipids in health and disease · 2025Article
- Automated process assessment of primary healthcare for hyperlipidemia: preliminary findings and implications form Anhui, China.Lipids in health and disease · 2025Article
- Comparison of novel and traditional anthropometric indices in Eastern-China adults: which is the best indicator of the metabolically obese normal weight phenotype?BMC public health · 2024Article
- Exposure to volatile organic compounds is a risk factor for diabetes retinopathy: a cross-sectional study.Frontiers in public health · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo investigate the prevalence, awareness, treatment and control of dyslipidaemia and its associated factors in eastern China.
designCross-sectional study.
settingData were collected from the 2017 Nanjing Chronic Disease and Risk Factor Surveillance.
participantsThis study included 60 283 participants aged ≥18 years. OUTCOME MEASURES: Prevalence of dyslipidaemia was defined as self-reported history of dyslipidaemia and/or the use of lipid-lowering medication, and/or meeting at least one of the following during on-site investigation: total cholesterol ≥6.2 mmol/L, triglyceride ≥2.3 mmol/L, low-density lipoprotein cholesterol ≥4.1 mmol/L and high-density lipoprotein cholesterol <1.0 mmol/L. Dyslipidaemia awareness was defined as the proportion of patients with dyslipidaemia who explicitly indicate their awareness of having a diagnosis of dyslipidaemia. Treatment was based on medication use among individuals with dyslipidaemia. Control was defined as having dyslipidaemia, receiving treatment and achieving serum lipid control to the standard level. ANALYSIS: Complex weighting was used to calculate weighted prevalence. A two-level logistic regression model determined the influencing factors for dyslipidaemia prevalence, awareness, treatment and control.
resultsThe crude prevalence rate of dyslipidaemia was 28.4% (17 093 of 60 283). Among 17 093 patients with dyslipidaemia, the crude rates of awareness, treatment and control were 40.0% (n=6830), 27.5% (n=4695) and 21.9% (n=3736), respectively. The corresponding weighted prevalence rates were 29.8%, 41.6%, 28.9% and 22.9%. Older age (OR 2.03, 95% CI 1.82 to 2.23), urban residence (1.24, 1.19 to 1.31), higher education level (1.31, 1.21 to 1.42), current smoking (1.22, 1.15 to 1.29), alcohol consumption (1.20, 1.14 to 1.26), obesity (2.13, 1.99 to 2.29), history of hypertension (1.64, 1.56 to 1.71) and diabetes (1.92, 1.80 to 2.04) were identified as independent risk factors for dyslipidaemia (all p<0.001). Participants who were older, female, living in urban areas, had higher education levels, did not smoke or drink alcohol, had central obesity, had hypertension or had diabetes were more likely to be aware of their dyslipidaemia conditions, receive treatment and achieve serum lipid control to a standard level than their comparators (all p<0.05).
conclusionsThe prevalence of dyslipidaemia is relatively high in eastern China; however, awareness, treatment and control levels are relatively low.
Indexed as
Identifiers
38128931What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.